Key Points It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. 10 stocks we like better than Replimune Group › One day after enduring a nearly 40% decline in its share price, bitoech Replimune (NASDAQ: REPL) was also down on Friday, although nowhere near as steeply. The company's stock was in the red by almost 7%, which didn't look so hot next to the S&P 500's (SNPINDEX: ^GSPC) gain of 0.5%. A recommendation downgrade from a ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the best performers on Thursday. Replimune extended losses to a second consecutive day on Thursday, slashing 39.40 percent to close at $3.46 apiece after failing to clear regulatory challenges for its treatment candidate for melanoma. In a statement, Replimune Group, Inc. (NASDAQ:REPL) said it met with the US Food and Drug Administration on Tuesday to discuss the agency’s complete response letter fo ...

Key Points A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. 10 stocks we like better than Replimune Group › On Thursday, Replimune (NASDAQ: REPL) had a crucial meeting with federal regulators regarding one of its leading drug candidates. While the outcome of the event wasn't necessarily negative, it left the future of the drug up in the air, and investors didn't like that uncertainty. As a result, they assertively traded ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=167833&from=3  CLASS PERIOD: ...

Accessibility StatementSkip Navigation REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about 45% during intraday trading after the company announced that it completed a Type A meeting with the FDA on September 16 to discuss its Biologics License Application ("BLA") for lead drug candidate RP1 but "a path forward under ...

Replimune Group, Inc. (REPL) plunged 44.74 percent to $3.15 on Thursday, down $2.55, after the company said it had completed a Type A meeting with the U.S. Food and Drug Administration regarding the complete response letter tied to its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma. The stock opened at $4.12 and traded between $3.15 and $4.44, compared with a prior close of $5.71 on the Nasdaq. Trading volume surged to 15.9 million shares, well above the average o ...

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group, Inc. (Nasdaq: REPL) and certain of its executives. Investors who have lost money in their Replimune Group, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/repl.  What is this all about? Replimune’s stock fell over 70% on July 22, following an announcement tha ...

WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) on September 16th to discuss the complete response letter (CRL) for the Company’s Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma. The company is ev ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CLASS PERIOD: November 22, 2024 to July 21, 2025 ALLEGATIONS: The complaint allege ...

Accessibility StatementSkip Navigation  LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead ...